The subsequent discovery of ROS1 and RET rearrangements as potentially treatable targets suggested that several chromosomal translocations and corresponding gene fusions may serve as a driving force for NSCLC (12-16). The gene discussed is RET; the disease is non-small cell lung carcinoma.